How Pfizer Stock Can Rebound

1. Novo Nordisk bids $8.5 billion for Metsera, surpassing Pfizer's $7.3 billion offer. 2. Competition intensifies in the lucrative obesity drug market affecting PFE's strategy. 3. Pfizer shows potential for significant stock rallies, historically over 30% gains noted. 4. PFE's non-COVID revenue increased by 7% in Q2 2025, with anticipated cost reductions. 5. Past performance shows PFE vulnerability during economic downturns with significant stock drops.